Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway

These results provide a promising therapeutic approach for the treatment of wild-type EGFR non-small cell lung cancer.